|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT03306836 |
|
Date of registration:
|
31/05/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2
EAPCAAMHO2 |
|
Scientific title:
|
Multi-center,Single Blind,Prospective Randomized Controlled Trial of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation |
|
Date of first enrolment:
|
September 2016 |
|
Target sample size:
|
408 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT03306836 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Yong Cao, Doctor |
|
Address:
|
|
|
Telephone:
|
010-67096510 |
|
Email:
|
caoyong6@hotmail.com |
|
Affiliation:
|
|
|
|
Name:
|
Yong Cao, M.D. |
|
Address:
|
|
|
Telephone:
|
010-67096523 |
|
Email:
|
caoyong6@hotmail.com |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
1.All patients undergoing hybird surgery.
Exclusion Criteria:
1. Poor general condition , severe primary disease, surgical contraindications
2. Patient or family refused surgery
3. Fusiform aneurysm,Traumatic aneurysm,Infectious aneurysms
4. Combined with other hemorrhagic cerebrovascular disease
5. Combined with malignant brain tumor
6. Perinatal, Pregnancy
7. Patients unwilling to participate in the trial
Age minimum:
N/A
Age maximum:
70 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Cerebral Aneurysm
|
|
Arteriovenous Malformations
|
|
Intervention(s)
|
|
Drug: Heparin Sodium
|
|
Primary Outcome(s)
|
|
Changes in activated coagulation time safety coverage rate from the beginning of surgery to 48 hours after surgery
[Time Frame: From the beginning of surgery to 48 hours after surgery]
|
|
Secondary Outcome(s)
|
|
Changes in hemorrhage event rate from the beginning of surgery to 48 hours after surgery
[Time Frame: From the beginning of surgery to 48 hours after surgery]
|
|
Changes in ischemia event rate from the beginning of surgery to 48 hours after surgery
[Time Frame: From the beginning of surgery to 48 hours after surgery]
|
|
Intraoperative blood loss
[Time Frame: From the beginning of surgery to 48 hours after surgery]
|
|
Secondary ID(s)
|
|
2016YFC1301800-2
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|